Esaxerenone: A Comprehensive Clinical and Pharmacological Profile

1. Executive Summary

Esaxerenone is a novel, orally administered, non-steroidal, selective mineralocorticoid receptor (MR) antagonist. Developed by Daiichi Sankyo, it has received its first global approval in Japan for the treatment of hypertension and is under investigation for diabetic nephropathy. Its distinct chemical structure and high selectivity for the MR aim to overcome limitations associated with older, steroidal MRAs, particularly concerning hormonal side effects.

Pharmacokinetically, esaxerenone exhibits high oral bioavailability, a long plasma half-life supporting once-daily administration, and multiple metabolic pathways (primarily CYP3A-mediated oxidation, glucuronidation, and hydrolysis), which suggest a low potential for significant drug-drug interactions. Its disposition is largely unaffected by food or mild-to-moderate hepatic impairment. Pharmacodynamically, esaxerenone effectively blocks MR activation, leading to reduced blood pressure, natriuresis, and a decrease in urinary albumin-to-creatinine ratio (UACR) in relevant patient populations.

Clinical trials, predominantly in Japanese patients, have demonstrated esaxerenone's efficacy in essential hypertension, where it showed non-inferiority and, at higher doses, superiority to eplerenone in blood pressure reduction. In patients with type 2 diabetes and microalbuminuria, esaxerenone significantly improved UACR and reduced progression to overt nephropathy. Preliminary data also suggest potential benefits in heart failure with reduced ejection fraction.

The primary safety concern associated with esaxerenone, typical of the MRA class, is hyperkalemia. The risk necessitates careful patient selection and regular serum potassium monitoring, especially in individuals with renal impairment or those receiving concomitant medications that affect potassium levels. Notably, co-administration with SGLT2 inhibitors may attenuate this risk. Other adverse events are generally mild to moderate.

Esaxerenone represents a significant advancement in MRA therapy, offering a promising therapeutic option for hypertension and diabetic kidney disease due to its targeted mechanism, favorable pharmacokinetic profile, and demonstrated efficacy. Further research, including long-term cardiovascular outcome trials and studies in diverse ethnic populations, will be crucial to fully delineate its role in global clinical practice.

2. Introduction to Esaxerenone

Overview and Therapeutic Significance

Esaxerenone is an orally active, non-steroidal, selective mineralocorticoid receptor (MR) antagonist.[1] It was initially discovered by Exelixis and subsequently developed by Daiichi Sankyo for the treatment of conditions such as hypertension and diabetic nephropathies.[3] The development of Esaxerenone addresses an unmet need for MR antagonists with improved profiles compared to existing steroidal agents like spironolactone and eplerenone. While these older drugs are effective, their utility can be limited by hormonal side effects (e.g., gynecomastia with spironolactone) due to a lack of receptor selectivity, and for eplerenone, a shorter half-life often necessitates twice-daily dosing for optimal effect.[2] Esaxerenone's non-steroidal structure and high selectivity for the MR are designed to mitigate these limitations, potentially offering better tolerability and patient adherence in chronic disease management.

Chemical Identity and Properties

Esaxerenone is classified as a small molecule drug.[8] Its chemical and physical properties are summarized in Table 1.

Table 1: Esaxerenone - Key Identifiers and Properties

Feature	Detail	Reference(s)
Generic Name	Esaxerenone	User Query, 8
DrugBank ID	DB15207	User Query, 8
Type	Small Molecule	User Query, 8
CAS Number	1632006-28-0	User Query, 4
Synonyms	CS-3150, XL-550 (developmental codes); Minnebro™ (brand name in Japan)	1
Chemical Formula	C<sub>22</sub>H<sub>21</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S	4
Molecular Weight	Approx. 466.48 g/mol	4
Chemical Class	Non-steroidal Mineralocorticoid Receptor Antagonist; Aromatic anilide; Phenylpyrrole; Benzenesulfonyl compound	1
Appearance	Solid Powder	4
Water Solubility	0.00475 mg/mL (poorly soluble)	8
Other Solubilities	Soluble in DMSO	5

The developmental codes CS-3150 and XL-550 reflect its progression through different research and development phases and organizations. The non-steroidal nature of Esaxerenone is a fundamental aspect of its chemical identity, distinguishing it from earlier generations of MRAs and forming the basis for its enhanced receptor selectivity and potentially improved side effect profile. Its approval and marketing under the brand name Minnebro™ in Japan signify its transition from an investigational compound to a clinically available therapeutic agent in that region.

The non-steroidal chemical architecture of Esaxerenone is a critical design feature. This structural distinction from older steroidal MRAs, such as spironolactone and eplerenone, is intentionally engineered to achieve higher selectivity for the mineralocorticoid receptor. By minimizing interactions with other steroid hormone receptors (e.g., androgen, progesterone, glucocorticoid receptors), Esaxerenone aims to avoid the hormonal side effects that can compromise the tolerability and long-term adherence associated with these earlier agents.[2] This targeted approach is particularly relevant for chronic conditions like hypertension and diabetic kidney disease, where sustained treatment is often necessary.

The initial and primary focus of Esaxerenone's clinical development and subsequent regulatory approval has been in Japan.[1] This geographical concentration suggests that the early clinical data and specific characteristics of the Japanese patient population, such as the prevalence of salt-sensitive hypertension or particular pharmacogenomic factors, may have been especially conducive to demonstrating its favorable risk-benefit profile. This regional success likely shaped its broader global development strategy and indicates the importance of considering population-specific factors in drug development.

3. Mechanism of Action

Selective Mineralocorticoid Receptor (MR) Blockade

Esaxerenone exerts its therapeutic effects as a highly potent and selective non-steroidal antagonist of the mineralocorticoid receptor (MR).[1] The MR, a nuclear hormone receptor, is the primary target for aldosterone, the main endogenous mineralocorticoid. Aldosterone binding to MRs, particularly in the distal nephron of the kidney, initiates a signaling cascade that upregulates the expression and activity of epithelial sodium channels (ENaC) and the Na⁺/K⁺-ATPase pump. This results in increased sodium and water reabsorption from the tubular fluid into the bloodstream and enhanced potassium excretion into the urine.[2] This physiological process is vital for maintaining electrolyte and fluid balance and, consequently, blood pressure.

Esaxerenone competitively inhibits the binding of aldosterone to the MR.[2] By occupying the ligand-binding site, it prevents the conformational changes in the receptor necessary for its activation and subsequent gene transcription. This blockade effectively attenuates the downstream physiological effects of aldosterone, leading to increased sodium and water excretion (natriuresis and diuresis) and reduced potassium excretion (potassium retention). These actions collectively contribute to a reduction in extracellular fluid volume and, subsequently, a lowering of blood pressure.[2]

Molecular Interactions and Selectivity

The interaction of Esaxerenone with the MR is characterized by a unique binding mode within the ligand-binding domain, which differs from that of steroidal MRAs. This distinct interaction is believed to contribute to its potent antagonistic effect.[1] A key feature of Esaxerenone is its high degree of selectivity for the MR over other steroid hormone receptors, including the glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (PR). In vitro binding assays have demonstrated IC₅₀ values for MR in the nanomolar range (e.g., 9.4 nM), while its affinity for GR, AR, and PR is significantly lower, with IC₅₀ values exceeding 10,000 nM.[9] This represents a selectivity of over 1,000-fold for the MR.[5]

This high selectivity is clinically important because non-specific binding of older steroidal MRAs (like spironolactone) to androgen and progesterone receptors is responsible for undesirable hormonal side effects, such as gynecomastia, impotence, and menstrual irregularities.[2] The non-steroidal chemical structure of Esaxerenone underpins this enhanced selectivity, offering the potential for a more favorable side effect profile, particularly with long-term use. Furthermore, Esaxerenone functions as a "silent antagonist," meaning it effectively blocks the receptor without possessing any intrinsic agonistic activity.[5] This ensures a pure blockade of aldosterone's effects, preventing any partial receptor activation that could lead to complex or attenuated therapeutic outcomes.

Beyond Blood Pressure Regulation - Pleiotropic Effects

The pathophysiological role of MR overactivation extends beyond simple sodium and water retention. Excessive MR signaling is increasingly recognized as a contributor to inflammation, fibrosis, and adverse tissue remodeling in various organs, including the kidneys, heart, and vasculature. These detrimental effects are mediated by both genomic and non-genomic actions of aldosterone. By blocking MR activation, Esaxerenone is postulated to exert organ-protective effects that may be independent of, or additive to, its blood pressure-lowering actions. These pleiotropic effects, such as the observed anti-inflammatory and anti-fibrotic properties, are particularly relevant in the context of diabetic nephropathy and heart failure, where MR antagonism has shown therapeutic benefits.[6]

The combination of high selectivity and a non-steroidal backbone allows Esaxerenone to achieve potent MR blockade with a reduced likelihood of hormonal side effects. This targeted approach makes it a promising agent for chronic conditions where sustained MRA therapy is beneficial but may be limited by the tolerability issues of older, less selective agents. The "silent antagonist" nature of Esaxerenone ensures that its interaction with the MR results in a straightforward blockade of aldosterone-mediated signaling, without the complexities of partial agonism. This clear mechanism, preventing sodium/water reabsorption and promoting potassium retention, directly correlates with its primary pharmacodynamic outcomes—blood pressure reduction and UACR improvement—and also explains its principal safety consideration, the risk of hyperkalemia.

4. Pharmacological Profile

Pharmacokinetics (PK)

The pharmacokinetic profile of Esaxerenone has been characterized in healthy volunteers and patient populations, primarily in Japanese subjects.

• Absorption: Esaxerenone is rapidly absorbed after oral administration, facilitated by its high membrane permeability.[1] Peak plasma concentrations (T_max) are typically achieved within 1.5 to 4.0 hours post-dose.[4] The absolute oral bioavailability of Esaxerenone is high, reported to be approximately 89% in the fasting state and 90.8% in the fed state in healthy Japanese subjects, indicating near-complete absorption.[7] Steady-state concentrations are generally reached by day 4 of once-daily dosing.[7]
• Distribution: Esaxerenone exhibits low partitioning into blood cells, with a blood-to-plasma concentration ratio of approximately 0.628.[14] The apparent volume of distribution (V_z/F) has been reported in ranges such as 130-135 L [7] or 136.5-283.7 L [4] in multiple-dose studies in hypertensive patients. After intravenous administration in healthy subjects, the steady-state volume of distribution (V_ss) was approximately 1.27 L/kg.[15] Notably, unlike some steroidal MRAs that may concentrate preferentially in the kidneys, Esaxerenone appears to distribute more evenly between the heart and kidneys, a characteristic that could influence its tissue-specific effects and safety profile.[15]
• Metabolism: Esaxerenone undergoes extensive metabolism via multiple enzymatic pathways, a feature that generally contributes to a lower risk of clinically significant drug-drug interactions (DDIs) if one pathway is compromised.[1] The primary metabolic routes identified are:
• Oxidation: Mediated predominantly by cytochrome P450 3A (CYP3A4 and/or CYP3A5), this pathway accounts for approximately 30% of Esaxerenone's total clearance.[7]
• Glucuronidation: Esaxerenone is a substrate for multiple UDP-glucuronosyltransferase (UGT) isoforms.[7]
• Hydrolysis: Amide bond hydrolysis also contributes to its metabolism.[7] The existence of these varied metabolic pathways suggests a degree of metabolic redundancy, which can make the drug's pharmacokinetics less susceptible to alterations caused by inhibitors or inducers of a single enzyme or by genetic polymorphisms affecting one metabolic route.
• Key Metabolites: In human plasma, unchanged Esaxerenone is the most abundant circulating drug-related component, accounting for 40.8% of total radioactivity in an ADME study.[14] Significant identified metabolites include M4 (an O-glucuronide conjugate, 21.4% of plasma radioactivity), M11 (an acyl-glucuronide of an amide-bond hydrolysate, 8.0%), and M1 (a deshydroxyethyl form, 1.7%).[14]
• Excretion: Esaxerenone and its metabolites are eliminated from the body through both renal and fecal routes.[7] Following administration of radiolabeled Esaxerenone to healthy male subjects, high total radioactivity recovery (92.5%) was observed, with 38.5% of the administered dose excreted in urine and 54.0% in feces.[14] The excretion of unchanged Esaxerenone is minimal, with only 1.6% of the dose found in urine and 18.7% in feces as the parent drug.[14] This low urinary excretion of the active compound is a favorable characteristic, implying that renal impairment may have a limited impact on its systemic exposure, which is particularly relevant for a medication often used in patients with compromised kidney function, such as those with diabetic nephropathy.[1]
• Half-life (t_1/2): The terminal elimination half-life of Esaxerenone in plasma is consistently reported to be in the range of 19 to 25 hours.[1] The half-life of total radioactivity (parent drug plus metabolites) in blood and plasma was approximately 30 hours.[14] This pharmacokinetic property supports the convenience of a once-daily dosing regimen.[1]
• Influence of Hepatic Function: Clinical studies in Japanese subjects with mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) hepatic impairment have shown that such impairment does not have a clinically significant effect on the exposure (C_max and AUC) to a single dose of Esaxerenone when compared to subjects with normal hepatic function.[7] Consequently, dosage adjustments are generally not considered necessary for patients with mild to moderate hepatic impairment.[7]
• Influence of Renal Function: As suggested by its low urinary excretion of unchanged drug, the pharmacokinetics of Esaxerenone are not expected to be substantially altered by renal dysfunction.[14] Clinical data indicate similar exposure in elderly and non-elderly patients, and in those with normal versus moderately deteriorated renal function.[1]
• Influence of Food: The administration of Esaxerenone with or without food does not significantly impact its pharmacokinetic parameters, including C_max and AUC.[15] Bioavailability remains high (89.0% fasted vs. 90.8% fed). This lack of a significant food effect allows for flexibility in dosing administration relative to meals, which can improve patient convenience and adherence.[10]
• Role of Transporters: In vitro studies have identified Esaxerenone as a substrate for the efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).[14] However, given its high oral absorption and the minimal excretion of unchanged drug in both urine and feces, these transporters are not considered to be major determinants of Esaxerenone's overall absorption or elimination in vivo.[14]

The pharmacokinetic characteristics of Esaxerenone – including high oral bioavailability, a long half-life suitable for once-daily administration, multiple metabolic pathways that reduce the risk of significant drug-drug interactions, and minimal influence from food or mild-to-moderate hepatic impairment – collectively contribute to a predictable and convenient dosing profile. This is particularly advantageous for the long-term management of chronic conditions like hypertension and diabetic kidney disease.

Table 2: Summary of Key Pharmacokinetic Parameters of Esaxerenone

Parameter	Value	Population/Notes	Reference(s)
Absorption
Absolute Bioavailability	~89-91%	Healthy Japanese subjects, oral	7
T<sub>max</sub> (Time to Peak)	1.5 - 4.0 hours	Healthy subjects/patients, oral	4
Food Effect	Not clinically significant	Healthy Japanese subjects	10
Distribution
V<sub>d,ss</sub> (IV)	~1.27 L/kg	Healthy Japanese subjects	15
V<sub>z</sub>/F (oral)	130 - 284 L	Healthy subjects/patients (range from studies)	4
Blood-to-Plasma Ratio	0.628	Healthy male subjects	14
Metabolism
Pathways	Oxidation (CYP3A ~30%), Glucuronidation (UGTs), Hydrolysis	In vitro, Human ADME	1
Key Metabolites	M4 (O-glucuronide), M11 (acyl-glucuronide of hydrolysate), M1 (deshydroxyethyl)	Human plasma	14
Excretion
Routes	Urine (~38.5% of dose as total radioactivity), Feces (~54.0% of dose as total radioactivity)	Healthy male subjects, [<sup>14</sup>C]Esaxerenone	14
% Unchanged in Urine	1.6%	Healthy male subjects	14
% Unchanged in Feces	18.7%	Healthy male subjects	14
Elimination Half-life (t<sub>1/2</sub>)	19 - 25 hours (parent drug); ~30 hours (total radioactivity)	Healthy subjects/patients	1
Special Populations
Mild-Moderate Hepatic Impairment	No clinically relevant effect on exposure	Japanese subjects	7
Renal Impairment	Exposure not significantly affected by moderate renal impairment; low urinary excretion of parent drug	General observation, specific studies	1

Pharmacodynamics (PD)

• Effects on Blood Pressure: Esaxerenone demonstrates a dose-dependent reduction in blood pressure in preclinical models of hypertension, such as salt-sensitive hypertensive rats.[1] In clinical settings, it produces significant and sustained (24-hour) antihypertensive effects in patients with essential hypertension, both as a monotherapy and in combination with other antihypertensive agents.[1]
• Impact on Electrolytes and Renal Biomarkers:
• Consistent with its mechanism of MR blockade, Esaxerenone suppresses the aldosterone-induced decrease in the urinary sodium-to-potassium (Na⁺/K⁺) ratio in adrenalectomized rat models, indicating reduced sodium retention and potassium excretion.[1]
• In humans, treatment with Esaxerenone leads to an increase in plasma aldosterone concentrations and plasma renin activity. This is a physiological compensatory response to MR blockade and serves as a pharmacodynamic marker of target engagement.[18]
• A key pharmacodynamic effect, particularly relevant for its use in diabetic kidney disease, is the significant reduction in proteinuria, specifically the urinary albumin-to-creatinine ratio (UACR). This has been consistently observed in both animal models and clinical trials in patients with type 2 diabetes and microalbuminuria or overt nephropathy.[1]
• Effects on renal hemodynamics can include an initial, slight decrease in the estimated glomerular filtration rate (eGFR). This is often transient and may reflect a reduction in intraglomerular pressure, a potentially beneficial effect in hyperfiltering states like early diabetic nephropathy. Over the longer term, the drug aims to preserve renal function.[19]

The pharmacodynamic profile, characterized by increased plasma renin and aldosterone, alongside clinically beneficial outcomes like blood pressure reduction and UACR improvement, confirms robust engagement of the mineralocorticoid receptor by Esaxerenone. This direct link between its molecular action and observed therapeutic effects underscores its mechanism-based efficacy. Furthermore, the even distribution of Esaxerenone in critical target organs such as the heart and kidneys [15], as opposed to potentially more localized distribution patterns of some older steroidal MRAs, may contribute to more direct and beneficial tissue-level MR blockade. This could translate to enhanced organ protection beyond what is achieved through systemic blood pressure reduction alone, although further studies would be needed to fully elucidate such direct organ-specific benefits.

5. Clinical Development and Efficacy

The clinical development of Esaxerenone has primarily focused on its efficacy and safety in treating essential hypertension and diabetic nephropathy, with most pivotal studies conducted in Japanese patient populations.

Essential Hypertension

• ESAX-HTN Study (NCT02890173): Comparison with Eplerenone: This landmark Phase 3, multicenter, randomized, double-blind trial enrolled 1001 Japanese patients with essential hypertension. It compared the antihypertensive efficacy and safety of once-daily oral Esaxerenone (2.5 mg or 5 mg) against eplerenone (50 mg/day) over a 12-week treatment period.[1]
• The primary endpoint, change in sitting systolic and diastolic blood pressure (BP) from baseline, showed that Esaxerenone 2.5 mg/day was non-inferior to eplerenone 50 mg/day.
• Notably, Esaxerenone 5 mg/day demonstrated statistically significantly greater reductions in BP compared to the 2.5 mg/day dose of Esaxerenone.[17]
• Achievement of target BP (<140/90 mmHg) was higher with Esaxerenone 5 mg (41.2%) compared to eplerenone 50 mg (27.5%) and Esaxerenone 2.5 mg (31.5%).[17]
• All treatment groups exhibited persistent 24-hour antihypertensive effects, indicating sustained BP control over the dosing interval. The safety profile was comparable across the groups, with adverse events being generally mild to moderate.[17]
• These findings established Esaxerenone as an effective antihypertensive agent, with the 5 mg dose offering potentially greater BP reduction than a standard dose of eplerenone, coupled with the convenience of once-daily administration.
• Long-term Study (NCT02722265): Monotherapy and Combination Therapy: This Phase 3 study, also conducted in Japanese patients with essential hypertension, assessed the long-term (52-week) efficacy and safety of Esaxerenone, both as monotherapy and in combination with other antihypertensive drugs.[8]
• A post-hoc exploratory substudy focusing on a cohort of 25 treatment-naïve patients receiving Esaxerenone monotherapy (2.5 mg or 5 mg/day) reported consistent and sustained reductions in systolic/diastolic BP over the 52-week period (mean reduction of -23.5/-13.1 mmHg at week 52, p < 0.001 vs. baseline).[18]
• An interesting observation from urinary biomarker analysis in this substudy was that the BP-lowering effects of Esaxerenone appeared to be more pronounced in patients with higher baseline urinary sodium excretion. This suggests that the natriuretic effect of Esaxerenone, driven by MR blockade, is a significant component of its antihypertensive action and may help identify patients who are more likely to respond robustly to monotherapy, particularly those with salt-sensitive hypertension.[18]
• Efficacy in Specific Hypertensive Populations:
• Moderate Renal Impairment: Esaxerenone has demonstrated stable antihypertensive effects in patients with hypertension and moderate renal impairment, with manageable hyperkalemia when appropriate monitoring and dose titration are employed.[1] A completed Phase 3 trial specifically investigated its use in this population.[8]
• Severe Hypertension: The efficacy of Esaxerenone in severe hypertension has also been a subject of Phase 3 investigation.[8]
• Primary Aldosteronism: Clinical trial data indicate Esaxerenone's efficacy in patients with primary aldosteronism, including older individuals within this group.[8]

Diabetic Nephropathy (DN)

• ESAX-DN Phase 3 Study (JapicCTI-173695): This pivotal, randomized, double-blind, placebo-controlled trial evaluated the renoprotective effects of Esaxerenone in 455 Japanese patients with type 2 diabetes and microalbuminuria (incipient diabetic nephropathy), who were already receiving standard-of-care treatment with an angiotensin II receptor blocker (ARB) or an angiotensin-converting enzyme (ACE) inhibitor.[19]
• The primary endpoint was the rate of remission to normoalbuminuria (defined as UACR <30 mg/gCr and a ≥30% reduction in UACR from baseline) after 52 weeks of treatment. Esaxerenone treatment resulted in a significantly higher remission rate (22.1%) compared to placebo (4.0%).[20]
• Secondary endpoints further supported its renoprotective efficacy: Esaxerenone led to a significantly greater reduction in UACR from baseline (-58.3%) compared to placebo (+8.3%). Furthermore, progression from incipient to overt diabetic nephropathy (UACR ≥300 mg/gCr) was significantly reduced in the Esaxerenone group (1.4%) versus the placebo group (7.5%).[20]
• The incidence of confirmed hyperkalemia was 8.8% with Esaxerenone versus 2.2% with placebo, with elevations generally recovering after drug discontinuation.[20] These results provide strong evidence for Esaxerenone's ability to confer renal benefits beyond blood pressure control in early-stage diabetic kidney disease.
• EAGLE-DH Study: This study assessed Esaxerenone in hypertensive patients with type 2 diabetes and albuminuria, a notable proportion of whom were also receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors.[19]
• Esaxerenone demonstrated significant antihypertensive effects and reductions in UACR in this cohort.[19]
• A key finding was the potentially favorable impact of concomitant SGLT2 inhibitor use on the risk of hyperkalemia. The incidence of elevated serum potassium appeared lower in the EAGLE-DH study compared to historical data from Esaxerenone trials where SGLT2 inhibitor co-administration was not prevalent.[19] This suggests a possible synergistic or complementary effect, where SGLT2 inhibitors (which can sometimes have a mild potassium-lowering effect or are potassium-neutral) might help mitigate the hyperkalemic potential of Esaxerenone.

Other Investigational Areas

• Heart Failure with reduced Ejection Fraction (HFrEF): A retrospective, single-center study involving 50 Japanese hypertensive patients with HFrEF suggested that Esaxerenone was generally safe, with infrequent occurrences of hyperkalemia or hypotension at the doses used (average 2.0±0.9 mg/day). Furthermore, treatment was associated with an improvement (reduction) in brain natriuretic peptide (BNP) levels, a marker of heart failure severity.[21] While these findings are preliminary and from a retrospective analysis, they indicate a potential role for Esaxerenone in HFrEF, an established indication for other MRAs, warranting further prospective clinical trials.

The consistent demonstration of efficacy in reducing both blood pressure in hypertensive patients and albuminuria in those with diabetic nephropathy positions Esaxerenone as a potentially valuable therapeutic agent, particularly for individuals with cardiorenal metabolic syndrome. The observation of enhanced BP-lowering in patients with higher baseline urinary sodium excretion suggests that the natriuretic mechanism of Esaxerenone is clinically significant and may allow for better patient stratification or prediction of response. Moreover, the emerging data on its combination with SGLT2 inhibitors, particularly concerning the mitigation of hyperkalemia risk, is of considerable clinical interest, as this combination targets multiple pathophysiological pathways in diabetic kidney disease and heart failure.

Table 3: Overview of Major Clinical Trials for Esaxerenone

Trial Identifier/Name	Phase	Indication(s)	Patient Population	No. of Patients	Treatment Arms/Key Dosages	Duration	Primary Endpoint(s)	Key Efficacy Outcomes	Key Safety Findings (Hyperkalemia)	Reference(s)
ESAX-HTN (NCT02890173)	3	Essential Hypertension	Japanese adults with essential hypertension	1001	Esaxerenone 2.5 mg QD, Esaxerenone 5 mg QD, Eplerenone 50 mg QD	12 weeks	Change in sitting SBP/DBP	Esa 2.5mg non-inferior to Epl; Esa 5mg superior to Esa 2.5mg. Target BP (<140/90): Esa 2.5mg 31.5%, Esa 5mg 41.2%, Epl 27.5%. Sustained 24h effect.	Similar incidence across groups, mild/moderate.	1
NCT02722265	3	Essential Hypertension	Japanese adults with essential hypertension (monotherapy or combination)	N/A (substudy 25)	Esaxerenone 2.5 or 5 mg/day (monotherapy substudy)	52 weeks	Long-term safety & efficacy	Sustained SBP/DBP reduction at 52 weeks (-23.5/-13.1 mmHg). More pronounced effect with higher baseline urinary Na<sup>+</sup> excretion.	Not detailed for hyperkalemia in substudy abstract.	User Query, 8
ESAX-DN (JapicCTI-173695)	3	Type 2 Diabetes with Microalbuminuria (Incipient DN)	Japanese adults with T2D & microalbuminuria on ARB/ACEi	455	Esaxerenone (titrated) vs. Placebo	52 weeks	Remission to normoalbuminuria	UACR Remission: Esa 22.1% vs. Pbo 4.0%. UACR Reduction: Esa -58.3% vs. Pbo +8.3%. Reduced progression to overt DN: Esa 1.4% vs. Pbo 7.5%.	Esa 8.8% vs. Pbo 2.2%; recovered with discontinuation.	19
EAGLE-DH	N/A (Post-marketing)	Hypertension with Type 2 Diabetes & Albuminuria	Japanese adults with HTN, T2D, albuminuria (many on SGLT2 inhibitors)	93	Esaxerenone (dose not specified in abstract summary)	24 weeks	Change in BP and UACR	Significant reduction in BP and UACR.	Low incidence (1.1% K<sup>+</sup> ≥5.5 mEq/L with SGLT2i).	19
HFrEF Retrospective Study	N/A (Retrospective)	Hypertension with HFrEF	Japanese adults with HTN & HFrEF	50	Esaxerenone (mean 2.0±0.9 mg/day)	Mid-term ~167 days	Safety, change in BNP	Significant reduction in BNP.	No hyperkalemia (K<sup>+</sup> >5.5 mEq/L) observed. WRF (eGFR drop ≥20%) in 14% (short-term).	21

Abbreviations: BP = Blood Pressure; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; UACR = Urinary Albumin-to-Creatinine Ratio; DN = Diabetic Nephropathy; ARB = Angiotensin Receptor Blocker; ACEi = Angiotensin-Converting Enzyme inhibitor; Esa = Esaxerenone; Epl = Eplerenone; Pbo = Placebo; QD = Once Daily; K⁺ = Serum Potassium; eGFR = estimated Glomerular Filtration Rate; HFrEF = Heart Failure with reduced Ejection Fraction; BNP = Brain Natriuretic Peptide; Na⁺ = Sodium; HTN = Hypertension; T2D = Type 2 Diabetes; N/A = Not Applicable/Available from snippet.

6. Safety and Tolerability

The safety and tolerability profile of Esaxerenone has been evaluated in various clinical trials, primarily focusing on patients with hypertension and diabetic nephropathy.

Comprehensive Adverse Event Profile

Overall, Esaxerenone has been reported as generally well-tolerated in clinical studies, with most adverse events (AEs) being of mild to moderate severity.[1] In the EAGLE-DH study, which included hypertensive patients with type 2 diabetes (many on SGLT2 inhibitors), treatment-emergent adverse events (TEAEs) were reported in 45.2% of patients, and drug-related TEAEs occurred in 12.9%. The most frequently reported TEAE in this study was dizziness, occurring in 7.5% of patients.[19]

Hyperkalemia

Hyperkalemia (elevated serum potassium levels) is the most clinically significant and anticipated adverse effect associated with all mineralocorticoid receptor antagonists, including Esaxerenone, due to their mechanism of action involving potassium retention.[21]

• Incidence: The incidence of hyperkalemia varies depending on the patient population studied, baseline renal function, concomitant medications, and the definition of hyperkalemia used.
• In the ESAX-HTN study (essential hypertension), the incidence of hyperkalemia with Esaxerenone was comparable to that observed with eplerenone.[17]
• In the ESAX-DN study (diabetic nephropathy patients on RAAS inhibitors), confirmed hyperkalemia was observed in 8.8% of patients treated with Esaxerenone compared to 2.2% in the placebo group. These elevations were generally manageable and resolved upon discontinuation of the drug.[20]
• In the EAGLE-DH study (hypertensive T2D patients, many on SGLT2 inhibitors), the incidence of hyperkalemia (K⁺ ≥5.5 mEq/L) was notably low at 1.1%, with no patients experiencing K⁺ levels ≥6.0 mEq/L.[19] This suggests a potentially lower risk when Esaxerenone is co-administered with SGLT2 inhibitors.
• In a retrospective study of hypertensive patients with HFrEF receiving low-dose Esaxerenone, no instances of hyperkalemia (K⁺ >5.5 mEq/L) were reported among the 50 patients.[21]
• Risk Factors: Factors that may increase the risk of developing hyperkalemia include pre-existing renal impairment (reduced eGFR), higher baseline serum potassium levels, type 2 diabetes, and the concomitant use of other medications that can elevate potassium levels, such as RAAS inhibitors (ACEIs, ARBs), NSAIDs, potassium supplements, and potassium-sparing diuretics.[23]
• Management Strategies: Effective management of hyperkalemia is crucial for the safe use of Esaxerenone.[24] Key strategies include:
• Careful Patient Selection: Assessing baseline renal function and serum potassium levels to identify high-risk individuals.
• Regular Monitoring: Frequent monitoring of serum potassium is essential, particularly upon initiation of therapy and after any dose adjustments. Japanese labeling for Esaxerenone recommends measuring potassium levels before treatment, at 2 and 4 weeks post-initiation or dose titration, and regularly thereafter. Guidelines from organizations like KDOQI and AHA also provide recommendations for monitoring frequency when using RAAS inhibitors and MRAs.
• Dose Titration: Initiating treatment with a low dose of Esaxerenone (e.g., 1.25 mg or 2.5 mg) and titrating upwards based on clinical response and serum potassium levels can help mitigate the risk.[1]
• Medication Review: Avoiding or using with extreme caution concomitant potassium supplements and potassium-sparing diuretics.
• Dietary Advice: Patient education regarding dietary potassium intake may be beneficial.
• Awareness of Pseudohyperkalemia: Clinicians should be aware of factors that can lead to falsely elevated potassium readings, such as hemolysis during blood collection, delayed sample processing, or contamination of samples.[24] The observation in the EAGLE-DH study of a potentially attenuated hyperkalemia risk when Esaxerenone is combined with SGLT2 inhibitors is noteworthy. SGLT2 inhibitors can have a mild osmotic diuretic effect and may not significantly raise, or in some cases might slightly lower, serum potassium. This interaction could be clinically advantageous in managing patients who require both MRA and SGLT2 inhibitor therapy for cardiorenal protection.

Effects on Renal Function

Treatment with Esaxerenone can lead to an initial, often slight and transient, decrease in estimated glomerular filtration rate (eGFR).[21] This is a recognized hemodynamic effect of drugs that reduce intraglomerular pressure (such as MRAs and RAAS inhibitors) and does not necessarily indicate intrinsic nephrotoxicity. In the EAGLE-DH study, the mean change in eGFR from baseline to week 24 was -5.2 ± 7.9 mL/min/1.73 m².[19] In a retrospective study of HFrEF patients, Worsening Renal Function (WRF), defined as an eGFR reduction of ≥20%, was observed in 14% of patients in the short-term, particularly those initiated on higher doses (2.5 mg vs. 1.25 mg).[21] Despite these initial eGFR changes, long-term studies in diabetic nephropathy have consistently shown that Esaxerenone provides renoprotective benefits, primarily evidenced by significant reductions in UACR.[19] This suggests that the initial eGFR dip may be offset by long-term preservation of kidney function.

Hypotension

As an antihypertensive agent, Esaxerenone can cause hypotension, especially if baseline blood pressure is already well-controlled or if used concomitantly with other blood pressure-lowering medications. However, in the retrospective HFrEF study, where patients were often on multiple antihypertensives, no instances of symptomatic hypotension (systolic BP <90 mmHg) were reported.[13]

Drug Interactions

• CYP3A4-mediated Interactions: Esaxerenone is a substrate of the cytochrome P450 3A (CYP3A) enzyme system.[14]
• Coadministration with strong CYP3A inhibitors (e.g., itraconazole, ketoconazole) can increase the plasma exposure (AUC) of Esaxerenone by approximately 1.5-fold.[16]
• Conversely, coadministration with strong CYP3A inducers (e.g., rifampicin) can decrease Esaxerenone AUC by about one-third and shorten its elimination half-life.[16]
• Therefore, caution is advised when Esaxerenone is used concomitantly with strong modulators of CYP3A activity. Dose adjustments or enhanced monitoring may be necessary, particularly in patients with hepatic impairment.[16] The well-characterized nature of these CYP3A interactions allows for predictable management. The limited reliance of Esaxerenone on active transporters for its elimination [14] further simplifies its DDI profile compared to drugs that are heavily dependent on such transporters.
• Interactions with Potassium-Affecting Agents:
• Trimethoprim: Preclinical studies suggest trimethoprim can inhibit epithelial sodium channels, potentially amplifying the hyperkalemic effect of MRAs. A clinical study investigating the co-administration of Esaxerenone and trimethoprim found that while serum potassium levels tended to increase, the interaction was not considered highly notable and was influenced by baseline renal function and the dosage of trimethoprim.[25] Nevertheless, caution and close monitoring are warranted, especially in patients with renal impairment, given that more significant interactions have been reported with older MRAs like spironolactone.
• Potassium-Sparing Diuretics and Potassium Supplements: Concomitant use with Esaxerenone significantly increases the risk of hyperkalemia and is generally contraindicated or requires extreme caution and rigorous monitoring (this is a general class warning for MRAs). Japanese regulatory information has previously listed potassium iodide as contraindicated with Esaxerenone for hypertension, although this was later revised to a precaution for specific emergency thyroid protection scenarios.[11]
• RAAS Inhibitors (ACEIs, ARBs): Esaxerenone is often used adjunctively with RAAS inhibitors, particularly in diabetic nephropathy, as demonstrated in the ESAX-DN and EAGLE-DH trials. While this combination can provide additive cardiorenal benefits, it also inherently increases the risk of hyperkalemia, making vigilant serum potassium monitoring essential.[24]
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs can impair renal function and increase serum potassium levels, especially when used with RAAS inhibitors and MRAs. This combination should be used cautiously with appropriate monitoring (general MRA class warning).

Table 4: Summary of Key Safety Findings and Adverse Events for Esaxerenone

Adverse Event	ESAX-HTN (vs Eplerenone)	ESAX-DN (vs Placebo)	EAGLE-DH (many on SGLT2i)	HFrEF Study (Retrospective)	Notes
Hyperkalemia (K<sup>+</sup> ≥5.5 mEq/L or defined by study)	Similar to eplerenone	Esa: 8.8% vs Pbo: 2.2%	1.1% (K<sup>+</sup> ≥5.5); 0% (K<sup>+</sup> ≥6.0)	0% (K<sup>+</sup> >5.5 mEq/L)	Manageable with monitoring and dose adjustment. Risk influenced by renal function, baseline K<sup>+</sup>, and concomitant medications.
eGFR Decrease / WRF	Not detailed as primary AE	Not detailed as primary AE	Mean eGFR change -5.2 mL/min/1.73m²	WRF (eGFR drop ≥20%) in 14% (short-term)	Often transient or stabilizing; considered in context of overall renoprotection.
Hypotension	Not detailed as primary AE	Not detailed as primary AE	Not detailed as primary AE	0% (SBP <90 mmHg)	Monitor BP, especially with other antihypertensives.
Dizziness	Not detailed as primary AE	Not detailed as primary AE	7.5% (most frequent TEAE)	Not detailed	Common MRA-class related AE.
Overall AEs	Similar to eplerenone; mild/moderate	No new safety concerns	TEAEs: 45.2%; Drug-related: 12.9%	Not systematically reported	Generally well-tolerated.

Abbreviations: Esa = Esaxerenone; Epl = Eplerenone; Pbo = Placebo; K⁺ = Serum Potassium; eGFR = estimated Glomerular Filtration Rate; WRF = Worsening Renal Function; SBP = Systolic Blood Pressure; TEAE = Treatment-Emergent Adverse Event; SGLT2i = Sodium-Glucose Cotransporter 2 inhibitor.

Table 5: Clinically Significant Drug Interactions with Esaxerenone

Interacting Drug/Class	Mechanism of Interaction	Effect on Esaxerenone (PK/PD)	Effect of Esaxerenone on Other Drug	Clinical Recommendation/Management	Reference(s)
Strong CYP3A Inhibitors (e.g., itraconazole, ketoconazole)	Inhibition of CYP3A-mediated metabolism of Esaxerenone	Increased Esaxerenone AUC (~1.5-fold)	Not specified	Caution; monitor for Esaxerenone adverse effects. Consider dose adjustment if necessary.	16
Strong CYP3A Inducers (e.g., rifampicin)	Induction of CYP3A-mediated metabolism of Esaxerenone	Decreased Esaxerenone AUC (~1/3rd), shortened t<sub>1/2</sub>	Not specified	Caution; may lead to reduced efficacy of Esaxerenone. Avoid concomitant use if possible or monitor efficacy closely.	16
Trimethoprim	Potential inhibition of renal potassium excretion (e.g., via ENaC inhibition by trimethoprim)	Potential for increased serum potassium	Not specified	Caution, especially in renal impairment. Monitor serum potassium. Interaction may be less notable than with older MRAs.	25
Potassium-Sparing Diuretics (e.g., spironolactone, amiloride)	Additive potassium-retaining effects	Significantly increased risk of hyperkalemia	Not specified	Concomitant use generally contraindicated or requires extreme caution and very close potassium monitoring.	General MRA class warning
Potassium Supplements	Additive potassium load	Significantly increased risk of hyperkalemia	Not applicable	Concomitant use generally contraindicated or requires extreme caution and very close potassium monitoring.	General MRA class warning
RAAS Inhibitors (ACEIs, ARBs)	Additive potassium-retaining effects; altered renal hemodynamics	Increased risk of hyperkalemia; potential for eGFR decline	Not specified	Common combination in DN; requires diligent serum potassium and renal function monitoring.	24
NSAIDs	Impaired renal prostaglandin synthesis, reduced renal blood flow, potassium retention	Increased risk of hyperkalemia and acute kidney injury	Not specified	Use with caution, especially in elderly or renally impaired patients. Monitor renal function and serum potassium.	General MRA class warning

7. Dosage, Formulation, and Administration

Approved Formulations and Strengths

Esaxerenone is marketed in Japan under the brand name Minnebro™.[1] It is available as oral tablets in three dosage strengths:

• 1.25 mg tablets
• 2.5 mg tablets
• 5 mg tablets [1]

Recommended Dosing Regimens for Approved Indications (Hypertension in Japan)

The dosing of Esaxerenone for the treatment of essential hypertension in Japan is typically initiated and titrated as follows:

• Starting Dose: The usual starting dose is 2.5 mg administered orally once daily.[10]
• Titration: If the antihypertensive effect is insufficient, the dose can be increased to a maximum of 5 mg once daily. This titration is generally considered within 4 weeks of initiation.[16]
• Dose Adjustments: Dose adjustments may be necessary based on the patient's clinical response and, crucially, serum potassium levels to manage the risk of hyperkalemia.[16]
• In specific populations, such as those with HFrEF in a retrospective study, an average dose of 2.0±0.9 mg/day was utilized, suggesting that lower doses may also be employed depending on the clinical context and tolerability.[21]

Administration Guidelines

• Frequency: Esaxerenone is administered once daily, a regimen supported by its long elimination half-life.[1]
• Relation to Food: Pharmacokinetic studies have demonstrated that Esaxerenone can be taken with or without food, as food intake does not significantly alter its absorption or overall bioavailability.[10] This provides flexibility for patients regarding the timing of administration relative to meals. While one specific study protocol mentioned fasting conditions prior to dosing [7], broader pharmacokinetic assessments indicate no significant food effect on Esaxerenone's profile.[15]

8. Regulatory Status

Current Marketing Approvals

• Japan (PMDA): Esaxerenone, marketed as Minnebro™, received its first global regulatory approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in January 2019. The approved indication is for the treatment of hypertension.[1] It is also under continued development in Japan for diabetic nephropathy.[7]

Status in Other Regions (e.g., FDA, EMA)

The available research predominantly details Esaxerenone's development, clinical trials, and regulatory approval within Japan.

• There is no definitive information within the provided snippets to confirm marketing approval by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
• An isolated statement in one review article [3] suggested that Esaxerenone was approved by the FDA in 2021 for "cardio-renal protection in adults with CKD associated with type 2 diabetes." However, this statement is likely erroneous and may be a misattribution to Finerenone (Kerendia®), another non-steroidal MRA which did receive FDA approval for that indication in 2021. The overwhelming majority of other provided documents consistently point to Esaxerenone's approval being specific to Japan for hypertension.
• The current regulatory landscape for Esaxerenone appears to be primarily concentrated in Japan. Further verification from official FDA and EMA sources would be necessary to confirm its status in these regions, but based on the supplied information, widespread approval beyond Japan is not evident.

9. Expert Synthesis and Conclusion

Summary of Esaxerenone's Profile

Esaxerenone emerges as a novel, highly selective, non-steroidal mineralocorticoid receptor (MR) antagonist, representing a potentially significant advancement in the management of hypertension and diabetic kidney disease. Its chemical distinctiveness from older steroidal MRAs underpins a pharmacological profile characterized by high affinity and selectivity for the MR, minimizing off-target hormonal interactions. Pharmacokinetically, Esaxerenone is favorable, featuring good oral bioavailability, a long elimination half-life that accommodates convenient once-daily dosing, and metabolism through multiple pathways (CYP3A, UGTs, hydrolysis), which inherently reduces the risk of major drug-drug interactions. Furthermore, its absorption and disposition appear largely unaffected by food intake or mild-to-moderate hepatic impairment, adding to its clinical utility.

Clinically, Esaxerenone has demonstrated robust efficacy in reducing blood pressure in patients with essential hypertension, proving non-inferior and, at higher doses, superior to eplerenone. Crucially, in patients with type 2 diabetes and microalbuminuria, Esaxerenone has shown significant renoprotective effects, evidenced by a marked reduction in urinary albumin-to-creatinine ratio (UACR) and a decreased rate of progression to overt nephropathy.

Clinical Implications and Position in Therapy

The development of Esaxerenone addresses a clear need for MRAs with improved therapeutic indices. Its high selectivity offers the prospect of achieving desired MR blockade with a lower burden of the hormonal side effects that have historically limited the use of agents like spironolactone. The once-daily dosing regimen is a practical advantage over eplerenone, potentially enhancing long-term patient adherence, which is critical in managing chronic conditions.

The dual efficacy of Esaxerenone in lowering blood pressure and reducing albuminuria positions it as a particularly valuable agent for the large and growing population of patients with comorbid hypertension and type 2 diabetes at risk for or with established kidney disease. The primary safety consideration, consistent with the MRA class, is hyperkalemia. This risk underscores the necessity for careful patient selection (especially considering baseline renal function and potassium levels) and diligent monitoring of serum potassium, particularly upon initiation and dose titration, and in the presence of interacting medications. The observation from the EAGLE-DH study, suggesting that concomitant use of SGLT2 inhibitors might attenuate the risk of Esaxerenone-induced hyperkalemia, is of substantial clinical interest. This combination targets multiple pathophysiological mechanisms in cardiorenal metabolic disease and could offer both enhanced efficacy and improved safety regarding potassium homeostasis.

Future Research Directions and Unmet Needs

While the current data for Esaxerenone are promising, several areas warrant further investigation to fully establish its global clinical role:

• Long-Term Outcome Studies: Large-scale, long-term clinical trials focusing on hard cardiovascular and renal outcomes (e.g., reduction in cardiovascular mortality, progression to end-stage kidney disease, hospitalization for heart failure) are essential to confirm that the observed benefits on surrogate markers like blood pressure and UACR translate into improved patient prognoses.
• Comparative Effectiveness: Head-to-head trials comparing Esaxerenone with Finerenone, another novel non-steroidal MRA with proven cardiorenal benefits, would be highly informative for guiding clinical choices.
• Ethnic Diversity in Clinical Trials: The majority of pivotal clinical trial data for Esaxerenone originates from Japanese patient populations. Given potential ethnic differences in drug metabolism, pharmacodynamics, disease prevalence (e.g., salt sensitivity), and dietary habits, studies in more diverse global populations are crucial to ensure the generalizability of its efficacy and safety profile.
• Severe Renal and Hepatic Impairment: Data on the use of Esaxerenone in patients with severe renal impairment (e.g., eGFR <30 mL/min/1.73m²) or severe hepatic impairment are limited. Further studies are needed to define its safety and appropriate dosing, if any, in these high-risk groups.
• Broader Cardiovascular Indications: While preliminary data in HFrEF are encouraging, dedicated prospective trials are needed to evaluate its efficacy and safety in various heart failure phenotypes, including HFpEF, and in resistant hypertension.
• Pediatric Use: The safety and efficacy of Esaxerenone in pediatric populations have not been established.

In conclusion, Esaxerenone is a well-characterized, selective, non-steroidal MR antagonist with a compelling profile for the treatment of hypertension and the potential to mitigate diabetic kidney disease. Its favorable pharmacokinetics and demonstrated efficacy, coupled with a manageable safety profile (with appropriate potassium monitoring), position it as an important addition to the therapeutic armamentarium for cardiorenal conditions. Continued research will further refine its place in therapy and explore its full potential across diverse patient populations and related indications.

Works cited

1. [Pharmacological profile, clinical efficacy, and safety of esaxerenone ..., accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/32879177/
2. What is the mechanism of Esaxerenone? - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-esaxerenone
3. Esaxerenone: First Global Approval - ResearchGate, accessed May 12, 2025, https://www.researchgate.net/publication/331364951_Esaxerenone_First_Global_Approval
4. CAS 1632006-28-0 Esaxerenone - BOC Sciences, accessed May 12, 2025, https://www.bocsci.com/esaxerenone-cas-1632006-28-0-item-74260.html
5. Esaxerenone | CAS#1632006-28-0 | aldosterone receptor antagonist | MedKoo, accessed May 12, 2025, https://www.medkoo.com/products/7449
6. Esaxerenone - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/drug/1a52972faae143499bd17bc8e5efc97a
7. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment - PubMed Central, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6979450/
8. Esaxerenone: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed May 12, 2025, https://go.drugbank.com/drugs/DB15207
9. www.caymanchem.com, accessed May 12, 2025, https://www.caymanchem.com/product/41082#:~:text=Esaxerenone%20is%20a%20non%2Dsteroidal,IC50%20%3D%209.4%20nM).&text=It%20is%20selective%20for%20mineralocorticoid,%3E10%2C000%20nM%20for%20all)..%26text%3DIt%2520is%2520selective%2520for%2520mineralocorticoid,%253E10%252C000%2520nM%2520for%2520all).&sa=D&source=editors&ust=1747061895321079&usg=AOvVaw0--IrjckrNtlt6IcxH9nYb)
10. What is Esaxerenone used for? - Patsnap Synapse, accessed May 12, 2025, https://synapse.patsnap.com/article/what-is-esaxerenone-used-for
11. Report on Investigation Results - PMDA, accessed May 12, 2025, https://www.pmda.go.jp/files/000272716.pdf
12. Exelixis' Collaborator Daiichi Sankyo Receives Regulatory Approval ..., accessed May 12, 2025, https://www.biospace.com/exelixis-collaborator-daiichi-sankyo-receives-regulatory-approval-for-minnebro-esaxerenone-tablets-for-the-treatment-of-hypertension-in-japan
13. Esaxerenone (CS-3150) | 99.95%(HPLC) | In Stock | Mineralocorticoid Receptor inhibitor - Selleck Chemicals, accessed May 12, 2025, https://www.selleckchem.com/products/esaxerenone.html
14. Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone ..., accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/30541878/
15. Bioavailability of esaxerenone and effects of food on esaxerenone pharmacokinetics - ResearchGate, accessed May 12, 2025, https://www.researchgate.net/figure/Bioavailability-of-esaxerenone-and-effects-of-food-on-esaxerenone-pharmacokinetics_tbl2_333314907
16. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8724184/
17. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone ..., accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/31786983/
18. Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect - PubMed, accessed May 12, 2025, https://pubmed.ncbi.nlm.nih.gov/35976603/
19. Efficacy and Safety of Esaxerenone in Hypertensive Patients with ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10567833/
20. Daiichi Sankyo Announces Positive Results from ESAX-DN Phase 3 ..., accessed May 12, 2025, https://www.daiichisankyo.com/media/press_release/detail/index_3163.html
21. Safety and efficacy of esaxerenone in Japanese hypertensive ..., accessed May 12, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0259485
22. Esaxerenone Completed Phase 3 Trials for Essential Hypertension Treatment - DrugBank, accessed May 12, 2025, https://go.drugbank.com/drugs/DB15207/clinical_trials?conditions=DBCOND0029603&phase=3&purpose=treatment&status=completed
23. Minnebro (esaxerenone) News - LARVOL Sigma, accessed May 12, 2025, https://sigma.larvol.com/product.php?e1=407015&tab=newstrac&page=2
24. Management of hyperkalemia during treatment with ..., accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8019656/
25. Hyperkalemic effect of drug–drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study - PMC, accessed May 12, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11295366/